Esteve JL, Acosta R, Heredia B et al.
Clinica Mediterrania Medica, Valencia, Spain.
Obstet Gynecol 2008;112:1029–36.
Editor’s note: Uterine leiomyomas are the most commonly observed benign tumors in women of reproductive age. A variety of treatment modalities are available for these tumors including surgery with or without adjuvant gonadotropin-releasing hormone analogues, as well as the less invasive method of uterine artery embolization. Signaling via progesterone and its cognate receptor plays a role in the pathogenesis of leiomyomas. The nonsteroidal antiprogestogen mifepristone, at a variety of doses (up to 50 mg/day), has been shown to both reduce leiomyoma volume and improve symptoms. However, a minimum effective dose and optimum treatment duration remains to be established. Thus, the present authors evaluated the efficacy of two doses (5 and 10 mg/day) in the treatment of uterine myomas.